Feb 7 (Reuters) - Pliant Therapeutics Inc PLRX.O:
PLIANT THERAPEUTICS PROVIDES UPDATE ON BEACON-IPF, A PHASE 2B/3 TRIAL IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
PLIANT THERAPEUTICS INC - PAUSES ENROLLMENT AND DOSING IN BEACON-IPF PHASE 2B TRIAL
PLIANT THERAPEUTICS INC - CURRENTLY ENROLLED PATIENTS WILL REMAIN IN BEACON-IPF TRIAL
PLIANT THERAPEUTICS INC - INFORMING GLOBAL REGULATORY AUTHORITIES
PLIANT THERAPEUTICS: ENROLLMENT AND DOSING FOR ON BEACON-IPF PAUSED WHILE DATA IS REVIEWED TO UNDERSTAND DSMB'S RATIONALE
Source text: ID:nGNX6YK74b
Further company coverage: PLRX.O
((reuters.briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.